Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Future Catalysts | Learn about potential value drivers, including clinical trial results, strategic partnerships, and expansion into new genetic disorder indications |
Market Valuation | Analyst price targets range from $4 to $12 per share, reflecting diverse views on Design Therapeutics' potential in the competitive biotech landscape |
Pipeline Progress | Delve into the company's lead assets for Friedreich's ataxia and Fuchs corneal dystrophy, and the potential impact on DSGN's market position |
GeneTAC Innovation | Explore Design Therapeutics' novel geneTAC platform, combining ASO and small molecule approaches to target genetic disorders with high unmet needs |
Metrics to compare | DSGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDSGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.2x | −5.5x | −0.5x | |
PEG Ratio | 0.29 | −0.12 | 0.00 | |
Price / Book | 3.7x | 2.4x | 2.6x | |
Price / LTM Sales | - | 10.8x | 3.2x | |
Upside (Analyst Target) | 15.2% | 45.8% | 47.6% | |
Fair Value Upside | Unlock | −2.9% | 6.1% | Unlock |